HOLXHIGH SIGNALRISK10-K

HOLX has entered into a definitive merger agreement to be acquired by Blackstone funds, while experiencing significant financial deterioration with net income declining 28.3% and share count dropping by 4 million shares.

The addition of merger-related risk language indicates HOLX is in the process of being acquired by private equity firm Blackstone, which represents a major corporate development requiring regulatory approvals. The substantial decline in financial performance coupled with the reduced share count suggests potential financial distress or strategic repositioning ahead of the acquisition, creating uncertainty about deal completion and shareholder value.

Comparing 2025-11-18 vs 2024-11-27View on EDGAR →
FINANCIAL ANALYSIS

HOLX experienced broad-based financial deterioration with net income falling 28.3% to $565.7M, operating income declining 19.1% to $714.3M, and operating cash flow dropping 17.7% to $1.1B. The simultaneous 1.8% reduction in outstanding shares from 226.9M to 222.9M suggests share repurchases, but these were insufficient to offset the underlying operational weakness. This financial decline occurring alongside merger discussions with Blackstone raises questions about the company's standalone performance and the strategic rationale for the acquisition.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-28.3%
$789.5M$565.7M

Net income declined 28.3% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-19.1%
$882.6M$714.3M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Operating Cash Flow
Cash Flow
-17.7%
$1.3B$1.1B

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2025-11-18
PRIOR — 2024-11-27
ADDED
As of November 13, 2025, 222,905,228 shares of the registrant s Common Stock, $0.01 par value, were outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 37 Item 7A.
These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements including, but not limited to: the timing, receipt and terms and conditions of any required governmental and regulatory approvals of the proposed merger (the Merger ) pursuant to the definitive agreement we entered into to be acquired by funds managed by Blackstone Inc.
and international governmental, regulatory, fiscal, monetary and public health responses to such crises; risks related to our ability to protect our intellectual property rights; risks related to anticipated trends relating to our financial condition or results of operations, including the impact of interest rate and foreign currency exchange fluctuations; risks related to estimated asset and liability values; risks related to our compliance with covenants contained in our debt agreements; and risks related to our liquidity, capital resources and the adequacy thereof.
In addition, we offer bacterial vaginosis and candida vaginitis assays, or BV/CV, for the diagnosis of vaginitis, a common and complex ailment affecting millions of women a year.
+7 more — sign up free →
REMOVED
As of November 21, 2024, 226,941,217 shares of the registrant s Common Stock, $0.01 par value, were outstanding.
Management's Discussion and Analysis of Financial Condition and Results of Operations 35 Item 7A.
These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
In addition, we offer bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis, a common and complex ailment affecting millions of women a year.
Our assay portfolio also includes diagnostic tests for a range of acute respiratory infections, including SARS-CoV-2, various strains of influenza and parainfluenza, and respiratory syncytial virus, as well as a test for the detection of Group B Streptococcus, or GBS, that are run on the Panther Fusion system, a field upgradeable instrument addition to the base Panther system.
+7 more — sign up free →
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →